Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Fawzy, Ameenathul Mazaya (57204771086)"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry
    (2022)
    Romiti, Giulio Francesco (56678539100)
    ;
    Proietti, Marco (57202956034)
    ;
    Vitolo, Marco (57204323320)
    ;
    Bonini, Niccolò (57203751290)
    ;
    Fawzy, Ameenathul Mazaya (57204771086)
    ;
    Ding, Wern Yew (56141931000)
    ;
    Fauchier, Laurent (7005282545)
    ;
    Marin, Francisco (57212539524)
    ;
    Nabauer, Michael (7004310943)
    ;
    Dan, Gheorghe Andrei (57222706010)
    ;
    Potpara, Tatjana S. (57216792589)
    ;
    Boriani, Giuseppe (57675336900)
    ;
    Lip, Gregory Y. H. (57216675273)
    Background: Clinical complexity is increasingly prevalent among patients with atrial fibrillation (AF). The ‘Atrial fibrillation Better Care’ (ABC) pathway approach has been proposed to streamline a more holistic and integrated approach to AF care; however, there are limited data on its usefulness among clinically complex patients. We aim to determine the impact of ABC pathway in a contemporary cohort of clinically complex AF patients. Methods: From the ESC-EHRA EORP-AF General Long-Term Registry, we analysed clinically complex AF patients, defined as the presence of frailty, multimorbidity and/or polypharmacy. A K-medoids cluster analysis was performed to identify different groups of clinical complexity. The impact of an ABC-adherent approach on major outcomes was analysed through Cox-regression analyses and delay of event (DoE) analyses. Results: Among 9966 AF patients included, 8289 (83.1%) were clinically complex. Adherence to the ABC pathway in the clinically complex group reduced the risk of all-cause death (adjusted HR [aHR]: 0.72, 95%CI 0.58–0.91), major adverse cardiovascular events (MACEs; aHR: 0.68, 95%CI 0.52–0.87) and composite outcome (aHR: 0.70, 95%CI: 0.58–0.85). Adherence to the ABC pathway was associated with a significant reduction in the risk of death (aHR: 0.74, 95%CI 0.56–0.98) and composite outcome (aHR: 0.76, 95%CI 0.60–0.96) also in the high-complexity cluster; similar trends were observed for MACEs. In DoE analyses, an ABC-adherent approach resulted in significant gains in event-free survival for all the outcomes investigated in clinically complex patients. Based on absolute risk reduction at 1 year of follow-up, the number needed to treat for ABC pathway adherence was 24 for all-cause death, 31 for MACEs and 20 for the composite outcome. Conclusions: An ABC-adherent approach reduces the risk of major outcomes in clinically complex AF patients. Ensuring adherence to the ABC pathway is essential to improve clinical outcomes among clinically complex AF patients. © 2022, The Author(s).
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Impact of ABC (Atrial Fibrillation Better Care) pathway adherence in high-risk subgroups with atrial fibrillation: A report from the ESC-EHRA EORP-AF long-term general registry
    (2023)
    Ding, Wern Yew (56141931000)
    ;
    Proietti, Marco (57202956034)
    ;
    Romiti, Giulio Francesco (56678539100)
    ;
    Vitolo, Marco (57204323320)
    ;
    Fawzy, Ameenathul Mazaya (57204771086)
    ;
    Boriani, Giuseppe (57675336900)
    ;
    Marin, Francisco (57212539524)
    ;
    Blomström-Lundqvist, Carina (55941853900)
    ;
    Potpara, Tatjana S. (57216792589)
    ;
    Fauchier, Laurent (7005282545)
    ;
    H Lip, Gregory Y. (57216675273)
    Background: Effects of Atrial Fibrillation Better Care (ABC) adherence among high-risk atrial fibrillation (AF) subgroups remains unknown. We aimed to evaluate the impact of ABC adherence on clinical outcomes in these high-risk patients. Methods: EORP-AF General Long-Term Registry is a prospective, observational registry from 250 centres across 27 European countries. High-risk patients were defined as those with either CKD (eGFR <60 mL/min/1.73m2), elderly patients (≥75 years) or prior thromboembolism. Primary outcome was a composite event of all-cause death, thromboembolism and acute coronary syndrome. Results: 6646 patients with AF were screened (median age was 70 [IQR 61 – 77] years; 40.2% females). There were 3304 (54.2%) patients with either CKD (n = 1750), older age (n = 2236) or prior thromboembolism (n = 728). Among these, 924 (28.0%) were managed as adherent to ABC. At 2-year follow-up, 966 (14.5%) patients reported the primary outcome. The incidence of the primary outcome was significantly lower in high-risk patients managed as adherent to ABC pathway (IRR 0.53 [95%CI, 0.43 – 0.64]). Consistent results were obtained in the individual subgroups. Using multivariable Cox proportional hazards analysis, ABC adherence in the high-risk cohort was independently associated with a lower risk of the primary outcome (aHR 0.64 [95%CI, 0.51 – 0.80]), as well as in the CKD (aHR 0.51 [95%CI, 0.37 – 0.70]) and elderly subgroups (aHR 0.69 [95%CI, 0.53 – 0.90]). Overall, there was greater reduction in the risk of primary outcome as more ABC criteria were fulfilled, both in the overall high-risk patients (aHR 0.39 [95%CI, 0.25 – 0.61]), as well as in the individual subgroups. Conclusion: In a large, contemporary cohort of patients with AF, we demonstrate that adherence to the ABC pathway was associated with a significant benefit among high-risk patients with either CKD, advanced age (≥75 years old) or prior thromboembolism. © 2022 European Federation of Internal Medicine
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Optimal Medical Therapy for Heart Failure and Integrated Care in Patients With Atrial Fibrillation: A Report From the ESC-EHRA EORP Atrial Fibrillation Long-Term General Registry
    (2025)
    Bonini, Niccolò (57203751290)
    ;
    Proietti, Marco (57202956034)
    ;
    Romiti, Giulio Francesco (56678539100)
    ;
    Vitolo, Marco (57204323320)
    ;
    Fawzy, Ameenathul Mazaya (57204771086)
    ;
    Ding, Wern Yew (56141931000)
    ;
    Imberti, Jacopo Francesco (57212103023)
    ;
    Fauchier, Laurent (7005282545)
    ;
    Marin, Francisco (57212539524)
    ;
    Nabauer, Michael (7004310943)
    ;
    Dan, Gheorghe Andrei (57222706010)
    ;
    Potpara, Tatjana S. (57216792589)
    ;
    Boriani, Giuseppe (57675336900)
    ;
    Lip, Gregory Y. H. (57802425600)
    BACKGROUND: Heart failure (HF) often occurs in patients with atrial fibrillation (AF), with a major impact on prognosis. Few data are available on the effect of integrated treatment strategies to improve prognosis in patients with AF. We aimed to evaluate the association between HF (according to left ventricular ejection fraction [LVEF]), HF optimal medical therapy and adherence to the Atrial Fibrillation Better Care pathway, and major outcomes in patients with AF. METHODS AND RESULTS: From the ESC-EHRA EORP-AF (European Society of Cardiology–European Heart Rhythm Association EURObservational Research Programme in Atrial Fibrillation) General Long-Term Registry, we evaluated patients with HF, categorized according to LVEF (HF with reduced ejection fraction, HF with mildly reduced ejection fraction, HF with preserved ejection fraction). Optimal medical therapy for HF was guidelines-defined. The primary end point was the composite of all-cause death and major adverse cardiovascular events. From the original cohort, 9373 (84.5%) patients were included in this analysis (median age, 71 [interquartile range, 62–77] years; 39.9% women). Compared with no HF, all HF categories were associated with an increased risk of the primary composite outcome, with highest figures observed for HF with reduced ejection fraction (hazard ratio [HR], 2.36 [95% CI, 2.00–2.78]). The risk was reduced in patients with AF and HF adherent to optimal medical therapy (HR, 0.83 [95% CI, 0.70–0.98]), as well as in those adherents to the Atrial Fibrillation Better Care pathway (HR, 0.65 [95% CI, 0.48–0.88]). The effect of Atrial Fibrillation Better Care pathway was consistent across the spectrum of LVEF. CONCLUSIONS: Patients with AF and HF have a high risk of major adverse events, and this risk is inversely associated with LVEF. Atrial Fibrillation Better Care pathway adherent management is associated with improved clinical outcomes in patients with HF, across the spectrum of LVEF. © 2024 The Author(s).

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback